Duchow, Ankelien and Bellmann-Strobl, Judith and Friede, Tim and Aktas, Orhan and Angstwurm, Klemens and Ayzenberg, Ilya and Berthele, Achim and Dawin, Eva and Engels, Daniel and Fischer, Katinka and Flaskamp, Martina and Giglhuber, Katrin and Grothe, Matthias and Havla, Joachim and Huemmert, Martin W. and Jarius, Sven and Kaste, Matthias and Kern, Peter and Kleiter, Ingo and Klotz, Luisa and Korporal-Kuhnke, Mirjam and Kraemer, Markus and Krumbholz, Markus and Kuempfel, Tania and Lohmann, Lisa and Ringelstein, Marius and Rommer, Paulus and Schindler, Patrick and Schubert, Charlotte and Schwake, Carolin and Senel, Makbule and Then Bergh, Florian and Tkachenko, Daria and Tumani, Hayrettin and Trebst, Corinna and Vardakas, Ioannis and Walter, Annette and Warnke, Clemens and Weber, Martin S. and Wickel, Jonathan and Wildemann, Brigitte and Winkelmann, Alexander and Paul, Friedemann and Stellmann, Jan-Patrick and Haeussler, Vivien (2024) Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. ANNALS OF NEUROLOGY, 95 (4). pp. 720-732. ISSN 0364-5134, 1531-8249
Full text not available from this repository. (Request a copy)Abstract
Objective: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.Methods: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).Results: We included 483 patients: 298 AQP4-IgG(+) NMOSD, 52 AQP4-IgG(-)/MOG-IgG(-) NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG(-)/MOG-IgG(-) NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG(+) NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.Interpretation: AQP4-IgG(+) NMOSD, AQP4-IgG(-)/MOG-IgG(-) NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD.ANN NEUROL 2024
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | OPTICA SPECTRUM DISORDER; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS-OPTICA; DIAGNOSTIC-CRITERIA; MULTIPLE-SCLEROSIS; MULTICENTER; IGG; PREDICTORS; EFFICACY; FEATURES; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 Aug 2025 05:14 |
| Last Modified: | 06 Aug 2025 05:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65706 |
Actions (login required)
 |
View Item |
